Latus Bio Raises $97M Series A to Accelerate Huntington's Disease Gene Therapy

Why It Matters

A scalable, brain‑targeted gene therapy could transform treatment of Huntington’s disease, a currently incurable neurodegenerative disorder, and set a precedent for CNS gene‑editing approaches.

Key Takeaways

• Latus Bio raised $97M Series A to develop CNS‑targeted AAVs.
• AAV-DB-3 delivers gene therapy to deep brain regions at low doses.
• Therapy targets MSH3 to curb CAG repeat expansion in Huntington’s disease.
• Single‑hemisphere infusion achieves broad striatal and cortical transduction.
• IND filing for LTS‑201 planned for late 2026.

Pulse Analysis

Huntington’s disease (HD) remains one of the most challenging neurodegenerative disorders, driven by an expanded CAG repeat in the huntingtin gene that leads to toxic protein aggregation. Traditional drug approaches have struggled to reach the deep brain structures where pathology originates, and systemic delivery of viral vectors often results in high peripheral exposure and prohibitive manufacturing costs. Recent advances in adeno‑associated virus (AAV) engineering, combined with machine‑learning‑guided capsid design, are reshaping the therapeutic landscape by promising more precise, efficient, and scalable delivery to the central nervous system.

At the forefront of this shift is AAV‑DB‑3, a capsid identified by Davidson’s team after screening tens of millions of variants in mouse and non‑human primate models. The vector demonstrates superior transduction of deep‑layer cortical neurons and striatal regions, achieving robust gene expression with doses far lower than those required for conventional serotypes like AAV5. In primate studies, a single infusion per hemisphere delivered the therapeutic payload—an artificial microRNA silencing the DNA‑repair protein MSH3—resulting in a 48‑94 percent knockdown and a projected multi‑year delay in somatic CAG expansion.

The commercial implications are equally compelling. Latus Bio’s $97 million Series A financing underscores investor confidence in a platform that could address not only HD but a broader class of repeat‑expansion disorders. With an IND submission for LTS‑201 slated for late 2026, the company is positioned to be a first mover in a market projected to exceed $2 billion as gene‑editing therapies mature. Success would validate a scalable, brain‑specific delivery paradigm, potentially accelerating development pipelines for other CNS indications and reshaping the economics of gene‑therapy manufacturing.

Deal Summary

Latus Bio, a biotech startup co-founded by geneticist Beverly Davidson, announced a $97 million Series A financing in May 2026 to advance its AAV-based gene therapy platform for Huntington's disease. The round, disclosed earlier this month, will fund development of its lead program LTS-201 and further capsid engineering.